New cancer drug enters first human tests
NCT ID NCT05351697
Summary
This was an early-stage study to test the safety and find the right dose of a new drug called BR105 in adults with advanced cancers that have not responded to standard treatments. Researchers gave the drug by IV infusion and closely monitored patients for side effects over 21 days. The goal was to see how much of the drug the body could tolerate and to gather initial signs of whether it might help control tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100000, China
Conditions
Explore the condition pages connected to this study.